Fig. 9: The antitumor effect and ICD induction of different treatments in RM−1 tumor-bearing C57BL/6J male mice. | Nature Communications

Fig. 9: The antitumor effect and ICD induction of different treatments in RM−1 tumor-bearing C57BL/6J male mice.

From: Engineering nanozyme immunomodulator with magnetic targeting effect for cascade-enzyodynamic and ultrasound-reinforced metallo-immunotherapy in prostate carcinoma

Fig. 9

a Schematic illustration of the procedures of ZFPG-mediated SDT; b average body weight curves of mice after varied treatments (n = 5 biologically independent samples, mean ± SD); c relative tumor volume curves of mice after varied treatments (n = 5 biologically independent samples, mean ± SD); d average tumor weight after various treatments (G1: Control, G2: US, G3: ZFP, G4: ZFPG, G5: ZFP + US, G6: ZFPG + US, n = 5 biologically independent samples, mean ± SD, statistical significance was calculated by one-way ANOVA test); e–g the slice fluorescence intensity of e CRT, f HMGB1, and g HSP90 after different treatments (G1: Control, G2: US, G3: ZFP, G4: ZFPG, G5: ZFP + US, G6: ZFPG + US, n = 3 biologically independent samples, mean ± SD, statistical significance was calculated by one-way ANOVA test); and h fluorescence images of tumor slices after CRT, HMGB1, and HSP90 immunofluorescence staining (Red channel: CRT and HSP90, Green channel: HMGB1, Blue channel: DAPI, G1: Control, G2: US, G3: ZFP, G4: ZFPG, G5: ZFP + US, G6: ZFPG + US, scale bar: 100 µm). Source data are provided as a Source Data file.

Back to article page